Previous Article | Next Article 
Journal of Clinical Microbiology, June 2003, p. 2587-2592, Vol. 41, No. 6
0095-1137/03/$08.00+0 DOI: 10.1128/JCM.41.6.2587-2592.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Phenotypic Description and Antimicrobial Susceptibilities of Aerococcus sanguinicola Isolates from Human Clinical Samples
Richard Facklam,1* Marguerite Lovgren,2 Patricia Lynn Shewmaker,1 and Gregory Tyrrell2
Centers for Disease Control and Prevention, Atlanta, Georgia 30333,1
National Center for Streptococcus, Edmonton, Alberta, Canada T6G 2J22
Received 22 October 2002/
Accepted 28 February 2003

ABSTRACT
This report describes the clinical sources and phenotypic characterization
of 16 isolates of
Aerococcus sanguinicola. Sixteen conventional
tests were used to describe and differentiate the 16 isolates
of
A. sanguinicola from 30 strains of
Aerococcus viridans, 27
strains of
Aerococcus urinae, and a single strain each of
Aerococcus christensenii and
Aerococcus urinaehominis. The phenotypic characterizations
of the type strains for each species and 14
A. sanguinicola isolates were also compared in the two reference laboratories.
A. sanguinicola are catalase-negative, vancomycin-susceptible,
gram-positive cocci arranged in clusters and tetrads, as are
all
Aerococcus species except
A. christensenii (which is arranged
in short chains). All 16 isolates of
A. sanguinicola were leucine
aminopeptidase and pyrrolidonylarylamidase positive, which is
unique to this species among the aerococci. All
A. sanguinicola isolates grew in broth containing 6.5% NaCl, hydrolyzed hippurate,
and were variable in the bile-esculin test. None of the isolates
deaminated arginine or were Voges-Proskauer positive. The type
strain of
A. sanguinicola was isolated from a blood culture
of a patient living in Denmark. Seven additional isolates were
from patients living in Canada, all with urinary tract infections
(six were female). Eight isolates were from patients living
in five different states in the United States; five were from
patients with urinary tract infections, and three were from
blood cultures of one patient each with pneumonia, suspected
endocarditis, and unknown clinical conditions. The antimicrobial
susceptibility patterns were unremarkable; all isolates tested
were susceptible to penicillin, amoxicillin, cefotaxime, cefuroxime,
erythromycin, chloramphenicol, vancomycin, quinupristin-dalfopristin
(Synercid), rifampin, linezolid, and tetracycline. Six of the
15 cultures were resistant to ciprofloxacin and levofloxacin,
but all 15 strains were susceptible to sparfloxacin. High-level
resistance was detected for meropenem (2 strains) and trimethoprim-sulfamethonazole
(1 strain). Intermediate resistance was detected for trimethoprim-sulfamethoxazole
(10 strains) and clindamycin (3 strains).

INTRODUCTION
Aerococci are gram-positive cocci (GPC) that are arranged in
tetrads and clusters. No chains are observed when Gram stains
are prepared from growth in broth or agar cultures. Other genera
that are GPC and catalase-negative that form clusters or tetrads
(
Alloiococcus,
Dolosigranulum,
Gemella,
Helcococcus,
Pediococcus,
and
Tetragenococcus) are differentiated from the
Aerococcus species by a combination of phenotypic characteristics (
9).
Prior to 1992, only a single species,
Aerococcus viridans, was
included in the genus. Since 1992, four additional species have
been described:
Aerococcus urinae,
Aerococcus sanguinicola,
Aerococcus christensenii, and
Aerococcus urinaehominis. Prior
to the description of the new species,
Aerococcus viridans was
the only non-chain-forming GPC that was pyrrolidonylarylamidase
(PYR) positive and leucine aminopeptidase (LAP) negative. The
description of the new species
Aerococcus urinae complicated
the differentiation of the
Aerococcus genus from the other non-chain-forming
GPC because
A. urinae cultures gave reactions in PYR and LAP
opposite to those of
A. viridans (
1). With the description of
additional species of aerococci,
A. sanguinicola (
14),
A. christensenii (
8), and
A. urinaehominis (
13), the differentiation of the members
of the genus
Aerococcus from the other non-chaining-forming
GPC became even more difficult. The descriptions of the latter
three species were made with a single strain each and based
on the uniqueness of their 16S rRNA gene sequences. Phenotypic
testing of a single strain is meager evidence for establishing
schemes for the identification of bacterial species. It is the
intent of this communication to establish a scheme for the differentiation
and identification of
A. viridans,
A. urinae, and
A. sanguinicola.
We also wished to evaluate commercially available products distributed
for the identification of GPC for the capacity to identify
A. sanguinicola. Since none of these products have this species
in their data banks, the correct identification would be "unacceptable
profile (or identification)," "unidentified," or "no match."
Identification of
A. sanguinicola strains as any other bacterium
would be an incorrect answer and a reflection of the nonspecific
nature of the data bank. A third goal of this study was to determine
if the antimicrobial susceptibility patterns of
A. sanguinicola are different from those of related species.

MATERIALS AND METHODS
Unidentified, catalase-negative, non-chain-forming GPC were
retrieved from culture collections at the Centers for Disease
Control and Prevention, Atlanta, Ga. (CDC), and the National
Center for Streptococcus, Edmonton, Alberta, Canada (NCS). Cultures
were received at these two national reference laboratories from
state and provincial health departments from both countries.
Reference and type strains for all
Aerococcus species were obtained
from the American Type Culture Collection (Manassas, Va.) or
the Culture Collection of the University of Göteborg (Göteborg,
Sweden).
Cultures were tested in both reference laboratories in a battery of conventional tests as previously described (9). Fourteen strains presumptively identified as A. sanguinicola were exchanged and tested in conventional tests and in commercial products designed to identify GPC.
All strains were tested for reaction in the AccuProbe Enterococcus culture identification test (GenProbe Inc., San Diego, Calif.). Five strains were sent to David Collins and Paul Lawson, University of Reading, Reading, United Kingdom, for 16S rRNA sequencing and to Enevold Falsen, University of Göteborg, for whole-cell protein analysis.
All strains were tested in the following commercially available identification systems: Rapid ID 32 Strep (ID 32), the API 20 Strep systems, and the Vitek gram-positive identification system. Cards were purchased from bioMerieux-Vitek (Hazelwood, Mo.) and tested on the Vitek system with analysis software version AMS-R07.01.
Rapid Pos ID panels were purchased from Dade MicroScan, Inc. (Sacramento, Calif.), and tested with the MicroScan WalkAway system, analysis software version 22.28. Cellular fatty acid analysis was performed with the Sherlock microbial identification (MIDI) system, software version 3.10, and the Clin40 library (Microbial ID, Inc., Newark, Del.). A BBL Crystal GP gram-positive identification system was purchased from Becton Dickinson Microbiology Systems, Sparks, Md. The codes generated by each system were sent to the manufacturer for species identification.
MICs were determined by methods described by the National Committee for Clinical Laboratory Standards (NCCLS) for testing streptococci other than Streptococcus pneumoniae (16). Seventeen antimicrobial agents with various concentrations were tested in customized panels (PML Microbiologicals, Wilsonville, Oreg.) by using the microdilution method in Mueller-Hinton broth supplemented with 3% lysed horse blood. See Table 5 for antibiotics and concentrations that were tested.

RESULTS
The comparison of conventional tests used in the CDC and NCS
laboratories to characterize 14 strains of
A. sanguinicola is
shown in Table
1. Disagreement between laboratories was observed
with the bile-esculin (BE) test: the CDC laboratory recorded
all cultures as positive, but the NCS laboratory recorded only
five cultures as positive. Also, the NCS laboratory observed
that all cultures were positive for hydrolysis of hippurate,
but the CDC laboratory observed that 1 of the 14 cultures was
negative. Trehalose was fermented by all isolates in tests at
the CDC laboratory, but 1 of 14 isolates was negative at the
NCS laboratory. Reactions in the other eight tests matched perfectly
between laboratories.
View this table:
[in this window]
[in a new window]
|
TABLE 1. Comparison of conventional test results in two reference laboratories for the identification of A. sanguinicolaa
|
Since the cultures identified as
A. sanguinicola had phenotypic
characteristics similar to those of the enterococci, i.e., positive
reactions in PYR, LAP, BE, and NaCl tests, we tested all cultures
with the AccuProbe
Enterococcus identification test. All strains
were negative for
Enterococcus identification.
The five cultures sent to P. Lawson and D. Collins in England had 16S rRNA sequences highly similar to that of the type strain of A. sanguinicola. The same five strains sent to E. Falsen in Sweden had whole-cell protein profiles highly similar to that of the type strain of A. sanguinicola. These results indicate that the phenotypic characteristics of the cultures generated by the CDC and NCS laboratories with conventional tests were representative of the species A. sanguinicola.
Since A. viridans is listed in the database for all six commercial systems, the correct identification should be A. viridans for the type strain and two very well characterized reference strains of A. viridans. The data from testing six systems with the three strains are given in Table 2. ID 32 was tested in both CDC and NCS laboratories, and it identified all three strains as A. viridans but not in the same laboratory. The type strain of A. viridans, SS-1251, was erroneously identified as Streptococcus acidominimus at the NCS but correctly identified in the CDC laboratory. The Vitek system did not identify any of the three strains correctly. The MicroScan system identified all three strains as A. viridans. The MIDI system identified one strain, not the type strain of A. viridans, as A. viridans. The Crystal system correctly identified two reference strains but not the type strain. The API 20 Strep system identified all three strains correctly, but two of the strains were identified with low discrimination. Identification codes for A. urinae are included only in the Crystal system. The type strain for this species (SS-1320) was correctly identified by the Crystal system. Since identification codes for A. urinae are not included in the other five systems, the correct identification should be "unacceptable profile" or "unidentified." The ID 32 and Vitek systems gave these answers, but both the MicroScan and MIDI systems gave erroneous identifications as Gemella morbillorum and Streptococcus pyogenes, respectively (low similarity index). The API 20 Strep system incorrectly identified the type strain of A. urinae as S. acidominimus. Identification codes are not included in any of the data banks for A. sanguinicola, A. christensenii, or A. urinaehominis. Only 2 of 21 strains were correctly identified as "unacceptable profile" or "unidentified." Five of the 21 identifications were A. viridans at various percentages of likelihood (Table 2).
Ten cultures of
A. sanguinicola were tested in all commercial
rapid identification systems (Table
3). Since this species is
not included in the databases for these systems, the correct
identification should be "unacceptable profile," "unidentified,"
or "no match." Identifications provided by the manufacturer
for the profile codes provided by the CDC and NCS laboratories
differed somewhat for ID 32. Nine of 10 cultures were correctly
identified as "unacceptable profile" by the CDC laboratory (one
was identified as
A. viridans), but only five of the cultures
were correctly identified from the data provided by the NCS
laboratory (four were identified as
A. viridans, three as "doubtful
profile," and one as
S. acidominimus with low discrimination).
The Vitek system correctly reported four cultures of
A. sanguinicola as "unidentified" but incorrectly identified one as
A. viridans and five as other species or genera of bacteria (Table
3). The
MicroScan system correctly reported two cultures of
A. sanguinicola as unidentified but incorrectly identified two as
A. viridans and six as other species or genera of bacteria. The MIDI system
failed to correctly report any of the 10 cultures as unidentified:
3 cultures were identified as
A. viridans, and 7 were identified
as other bacterial species or genera, and all similarity indices
were <0.5 (Table
3). The Crystal system correctly identified
eight cultures of
A. sanguinicola as "unacceptable identification"
and the other two as
Corynebacterium renale. The API Strep system
identified 8 of the 10 cultures of
A. sanguinicola as
A. viridans and one each as
Streptococcus bovis and
S. acidominimus.
Table
4 lists the conventional tests that can be used to identify
the five species of
Aerococcus,
Dolosigranulum pigrum,
Helcococcus kunzii, and
Tetragenococcus halophilus. Identification of
A. christensenii,
A. urinaehominis, and
T. halophilus should be
approached with caution, since biochemical data for all of these
species are based on the description of one or two isolates.
The data listed in this table for
A. viridans and
A. urinae were taken from the results for GPC identified within the past
7 years in the
Streptococcus laboratory at the CDC. Sixteen
cultures were confirmed as
A. sanguinicola by phenotypic characteristics
determined by conventional testing. Only one has not been tested
in both laboratories.
Seven cultures were obtained from Canadian patients (six females
and one male) with urinary tract infections; all but one of
these patients were

79 years old. Eight cultures were obtained
from patients residing in the United States: five (two males
and three females, all more than 69 years of age) had urinary
tract infections, and three had positive blood cultures, one
with sepsis, one with suspected endocarditis, and the other
without a diagnosis. The remaining isolate was the type strain
isolated from a blood culture of a patient living in Denmark
(
14).
Table 5 lists the antimicrobial susceptibilities of 15 strains of A. sanguinicola to 17 different drugs. One culture failed to grow in the MIC panels. All cultures were susceptible to penicillin, amoxicillin, cefotaxime, cefuroxime, erythromycin, chloramphenicol, vancomycin, quinupristin-dalfopristin (Synercid), rifampin, linezolid, and tetracycline. Most of the susceptibility values were equal to or less than the lowest dilution of drug tested. Six of the 15 cultures were resistant to ciprofloxacin and levofloxacin, but all 15 strains were susceptible to sparfloxacin. Intermediate or high resistance to meropenem, clindamycin, trimethoprim-sulfamethoxazole and chloramphenicol was detected in a few strains (one to three cultures for each drug). The MIC interpretation as susceptible or resistant was obtained by using the NCCLS criteria for streptococci other than S. pneumoniae except for trimethoprim-sulfamethoxazole (SXT) and rifampin; criteria for S. pneumoniae were used for these two drugs (16).

DISCUSSION
Whole-cell protein analysis and 16S rRNA gene sequencing were
performed for 5 of the 16 strains to validate the phenotypic
description. The 14 conventional tests listed in Table
4 along
with the Gram stain (cellular arrangement) and catalase test
can be used to phenotypically identify
A. sanguinicola. These
tests have proven to be reproducible in two laboratories, so
that the same identification should be attainable in any laboratory
performing the same tests. Other species, such as
A. viridans,
A. urinae,
D. pigrum, and
H. kunzii, can also be identified
with the same tests. The other catalase-negative, non-chain-forming
GPC, such as
Pediococcus,
Gemella, and
Alloiococcus, can be
selected out from this identification scheme with only a few
additional tests, such as those described in reference
7. Briefly,
the pediococci are the only catalase-negative, non-chain-forming
GPC that are vancomycin resistant, and the
Gemella species are
the only catalase-negative, non-chain-forming GPC that fail
to grow in 6.5% NaCl. Alloiococci fail to grow on sheep blood
agar plates and have been found only in ear fluids.
A. sanguinicola is not related to the subspecies of
A. urinae described by Christensen
et al. (
7). The phenotypic characteristics of each of the subspecies
of
A. urinae and
A. sanguinicola are distinct.
It is disappointing that the commercially available systems are not consistently capable of identifying reference strains of A. viridans. It is apparent that not all systems have used the same reference strains to document their database. It is also apparent that some of the systems are not restrictive enough to accurately identify Aerococcus species. It is probable that the identification was not accurate for the strains used to establish the databases, which results in erroneous matches in the database. Among the commercially available rapid identification systems, the ID 32 and Crystal systems would be the most convenient to improve, since they gave the correct response of "no identification"; adding profile numbers to the databases would easily provide for accurate identification for an appreciable number of strains. The other rapid systems will require significant retooling of their databases because of the number of erroneous identifications.
A. sanguinicola is found in human infections and is frequently identified in clinical samples from elderly female patients with urinary tract infections. A. sanguinicola is similar to A. urinae in clinical implication, as both were first described as causes of urinary tract infections (6, 24) and then later found to be associated with bacteremia, sepsis, and endocarditis (4, 12). A. sanguinicola has been isolated from blood cultures of patients with sepsis and endocarditis (this report). A. viridans, the first Aerococcus species described, has been isolated from patients with meningitis (15, 17), endocarditis (10, 18, 23), and bacteremia in granulocytopenia (11) and from human immunodeficiency virus-positive patients (19).
Whether it is clinically relevant to differentiate between the Aerococcus species remains to be determined.
Further investigation of the antimicrobial susceptibilities of the different species is required to resolve some of the apparent discrepancies in the literature. Penicillin resistance among strains of A. viridans has been reported (2, 4, 24). In an earlier study in this laboratory, it was found that nearly half the cultures of A. viridans were either highly or intermediately resistant to penicillin (2). One should interpret all published susceptibility reports for aerococci, including this report, with caution. The NCCLS does not have antimicrobial susceptibility criteria for the aerococci. Whether the interpretive criteria for streptococci other than S. pneumoniae or those for S. pneumoniae are valid for this genus can be questioned. Most reports describe single isolates or very small numbers of isolates, which indicates that A. viridans has various degrees of susceptibility to penicillin (10, 12, 15, 17-23). One report showed that 3 of 29 isolates were resistant (MIC of 0.25) to penicillin (11). Christensen and colleagues proposed using penicillin resistance as a potential way of differentiating between A. viridans (resistant) and A. urinae (susceptible) (5). The description of antimicrobial susceptibilities of A. urinae reported that these strains are susceptible to penicillin (4, 5, 6, 12, 24). We found that all 15 isolates of A. sanguinicola were susceptible to all beta-lactam antimicrobials.
The NCS has observed that all aerococci tested to date produce a zone of inhibition around a penicillin 10-unit disk (on blood agar plates), although the zone size may vary. Interestingly, an area of enhanced alpha hemolysis at the edge of the inhibitory zone may be observed for both A. sanguinicola and A. viridans, while A. urinae fails to produce this halo effect. This observation may provide a useful identification tool but does not imply susceptibility to penicillin. In 1989, Buu-Hoi and colleagues (3) reported that several strains of A. viridans had acquired the ermB gene of Enterococcus faecalis to confer erythromycin resistance and that other strains had acquired the tetM gene to code tetracycline resistance. We did not detect resistance to either erythromycin or tetracycline in the A. sanguinicola strains we investigated. One report of a single strain of A. urinae indicated that this isolate was susceptible to erythromycin (20). We found that 1 of the 15 strains of A. sanguinicola was resistant and 10 of the 15 strains were intermediately resistant to SXT. Kern and Vanek (11) reported that 19 of the 29 strains of A. viridans were resistant to SXT, while other reports (15, 24) indicated that all their strains were susceptible to SXT. Although there are no reports of SXT susceptibility studies for strains of A. urinae, several studies have reported sulfonamide resistance (4, 6, 12). Kern and Vanek (11) reported that 19 of the 29 strains of A. viridans in their studies were resistant to ofloxacin. We detected resistance to ciprofloxacin and levofloxacin but not sparfloxacin among the strains of A. sanguinicola in this study. We did not find any reported data on quinolone resistance in A. urinae. These data indicate that antimicrobial susceptibility studies should be performed on aerococci isolated from sterile sites as is currently done with the viridans group streptococci. It does not appear that antimicrobial resistance is a serious problem among the different species of aerococci at this time.

ACKNOWLEDGMENTS
We express our appreciation to P. A. Lawson and M. D. Collins
for determining the 16S rRNA gene sequences of five reference
strains and to E. Falsen for determining the similarity index
by whole-cell protein analysis of five representative strains.

FOOTNOTES
* Corresponding author: Mailing address: Centers for Disease Control & Prevention, Mail Stop C0-2, 1600 Clifton Rd., NE, Atlanta, GA 30333. Phone: (404) 639-1379. Fax: (404) 639-3123. E-mail:
Rfacklam{at}cdc.gov.


REFERENCES
1 - Aguirre, M., and M. D. Collins. 1992. Phylogenetic analysis of some Aerococcus-like organisms from urinary tract infections: description of Aerococcus urinae sp. nov. J. Gen. Microbiol. 138:401-405.[Abstract/Free Full Text]
2 - Bosley, G. S., P. L. Wallace, C. W. Moss, A. G. Steigerwalt, D. J. Brenner, J. M. Swenson, G. A. Hebert, and R. R. Facklam. 1990. Phenotypic characterization, cellular fatty acid composition, and DNA relatedness of aerococci and comparison to related genera. J. Clin. Microbiol. 28:416-421.[Abstract/Free Full Text]
3 - Buu-Hoi, A., C. Le Bouguenec, and T. Horaud. 1989. Genetic basis of antibiotic resistance in Aerococcus viridans. Antimicrob. Agents Chemother. 33:529-534.[Abstract/Free Full Text]
4 - Christensen, J. J., I. P. Jensen, J. Faerk, B. Kristensen, R. Skov, B. Korner, and the Danish ALO Study Group. 1995. Bacteremia/septicemia due to Aerococcus-like organisms: report of seventeen cases. Clin. Infect. Dis. 21:943-947.[Medline]
5 - Christensen, J. J., B. Korner, J. B. Casals, and N. Pringler. 1996. Aerococcus-like organisms: use of antibiograms for diagnostic and taxonomic purposes. J. Antimicrob. Chemother. 38:253-258.[Abstract/Free Full Text]
6 - Christensen, J. J., H. Vibits, J. Using, and B. Korner. 1991. Aerococcus-like organism, a newly recognized potential urinary tract pathogen. J. Clin. Microbiol. 29:1049-1053.[Abstract/Free Full Text]
7 - Christensen, J. J., A. M. Whitney, L. M. Teixeira, A. G. Steigerwalt, R. R. Facklam, B. Korner, and D. J. Brenner. 1997. Aerococcus urinae: intraspecies genetic and phenotypic relatedness. Int. J. Syst. Bacteriol. 47:28-32.[Abstract/Free Full Text]
8 - Collins, M. D., M. R. Gavidae, R. A. Hutson, M. Ohlen, and E. Falsen. 1999. Aerococcus christensenii sp. nov., from the human vagina. Int. J. Syst. Bacteriol. 49:1125-1128.[Abstract/Free Full Text]
9 - Facklam, R., and J. A. Elliott. 1995. Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci. Clin. Microbiol. Rev. 8:479-495.[Abstract]
10 - Janosek, J., J. Eckert, and A. Hudac. 1980. Aerococcus viridans as a causative agent of infectious endocarditis. J. Hyg. Epidemiol. Microbiol. Immunol. 24:92-96.[Medline]
11 - Kern, W., and E. Vanek. 1987. Aerococcus bacteremia associated with granulocytopenia. Eur. J. Clin. Microbiol. Infect. Dis. 6:670-673.
12 - Kristensen, B., and G. Nielson. Endocarditis caused by Aerococcus urinae, a newly recognized pathogen. Eur. J. Clin. Microbiol. Infect. Dis. 14:49-51.
13 - Lawson, P. A., E. Falsen, M. Ohlen, and M. D. Collins. 2001. Aerococcus urinaehominis sp. nov., isolated from human urine. Int. J. Syst. Evol. Microbiol. 51:683-686.[Abstract]
14 - Lawson, P. A., E. Falsen, K. Truber-Jensen, and M. D. Collins. 2001. Aerococcus sanguicola sp. nov., isolated from a human clinical source. Int. J. Syst. Evol. Microbiol. 51:475-479.[Abstract]
15 - Nathavitharana, K. A., S. N. Arseculeratne, H. A. Aponso, R. Vijeratnam, I. Jayasena, and C. Navaratnam. 1983. Acute meningitis in early childhood caused by Aerococcus viridans. Br. Med. J. 286:1248.
16 - National Committee for Clinical Microbiology Standards. 2002. Performance standards for antimicrobial susceptibility testing; twelfth informational supplement, vol. 22, M100-S12. National Committee for Clinical Microbiology Standards, Wayne, Pa.
17 - Park, J. W., and O. Grossman. 1990. Aerococcus viridans infection. Case report and review. Clin. Pediatr. 29:525-526.
18 - Pien, F. D., W. R. Wilson, K. Kunz, and J. A. Washington II. 1984. Aerococcus viridans endocarditis. Mayo Clin. Proc. 59:47-48.[Medline]
19 - Razeq, J. H., G. M. Thomas, and D. Alexander. 1999. The first reported case of Aerococcus bacteremia in a patient with HIV infection. Emerg. Infect. Dis. 5:838-839.[Medline]
20 - Skov, R. L., M. Klarlund, and S. Thorsen. 1995. Fatal endocarditis due to Aerococcus urinae. Diagn. Microbiol. Infect. Dis. 21:219-221.[CrossRef][Medline]
21 - Swanson, H., E. Cutts, and M. Lepow. 1996. Penicillin-resistant Aerococcus viridans bacteremia in a child receiving prophylaxis for sickle-cell disease. Clin. Infect. Dis. 22:387-388.[Medline]
22 - Uh, Y., J. S. Son, I. H. Jang, K. J. Yoon, and S. I. Hong. 2002. Penicillin-resistant Aerococcus viridans bacteremia associated with granulocytopenia. J. Korean Med. Sci. 17:113-115.[Medline]
23 - Untereker, W. J., and B. A. Hanna. 1976. Endocarditis and osteomyelitis caused by Aerococcus viridans. Mt. Sinai J. Med. 43:248-252.[Medline]
24 - Zhang, Q., C. Kwoh, S. Attorri, and J. E. Clarridge III. 2000. Aerococcus urinae in urinary tract infections. J. Clin. Microbiol. 38:1703-1705.[Abstract/Free Full Text]
Journal of Clinical Microbiology, June 2003, p. 2587-2592, Vol. 41, No. 6
0095-1137/03/$08.00+0 DOI: 10.1128/JCM.41.6.2587-2592.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Martin, V., Vela, A. I., Gilbert, M., Cebolla, J., Goyache, J., Dominguez, L., Fernandez-Garayzabal, J. F.
(2007). Characterization of Aerococcus viridans Isolates from Swine Clinical Specimens. J. Clin. Microbiol.
45: 3053-3057
[Abstract]
[Full Text]
-
Vela, A. I., Garcia, N., Latre, M. V., Casamayor, A., Sanchez-Porro, C., Briones, V., Ventosa, A., Dominguez, L., Fernandez-Garayzabal, J. F.
(2007). Aerococcus suis sp. nov., isolated from clinical specimens from swine. Int. J. Syst. Evol. Microbiol.
57: 1291-1294
[Abstract]
[Full Text]